— Publications

2018 Full-Year Results 




All financial reports


— Media releases


January 31, 2019

Valneva Reports Positive Initial Booster Data and Final Phase 1 Data for its Lyme Disease Vaccine Candidate

Read more


— Financial calendar


Upcoming events

Q1 2019 Interim Results
May 2, 2019


All dates




— Lyme Disease

Download brochure









    

— Our responsibility

Committed to people, protecting lives and the environment


Learn more

play video
“We have the only
clinical-stage vaccine program
against Lyme disease 
worldwide.”

Valneva's CEO Thomas Lingelbach
comments on Group Strategy

Subscribe to our Newsletter

mail-icon-lightblue.png


Contact Investor Relations

speech-balloon-icon-white.png

Please update your browser...